BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 1376311)

  • 1. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
    Debyser Z; Vandamme AM; Pauwels R; Baba M; Desmyter J; De Clercq E
    J Biol Chem; 1992 Jun; 267(17):11769-76. PubMed ID: 1376311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase.
    Debyser Z; Pauwels R; Baba M; Desmyter J; De Clercq E
    Mol Pharmacol; 1992 May; 41(5):963-8. PubMed ID: 1375320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
    Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
    Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds.
    Debyser Z; Pauwels R; Andries K; Desmyter J; Engelborghs Y; Janssen PA; De Clercq E
    Mol Pharmacol; 1992 Jan; 41(1):203-8. PubMed ID: 1370707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T).
    Balzarini J; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; Bathurst IC; Barr PJ; De Clercq E
    J Biol Chem; 1992 Jun; 267(17):11831-8. PubMed ID: 1376314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.
    de Vreese K; Debyser Z; Vandamme AM; Pauwels R; Desmyter J; de Clercq E; Anné J
    Virology; 1992 Jun; 188(2):900-4. PubMed ID: 1374986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives.
    Debyser Z; Pauwels R; Andries K; Desmyter J; Kukla M; Janssen PA; De Clercq E
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1451-5. PubMed ID: 1705038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
    Balzarini J; Karlsson A; De Clercq E
    Mol Pharmacol; 1993 Oct; 44(4):694-701. PubMed ID: 7694068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
    Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs.
    Pauwels R; Andries K; Debyser Z; Kukla MJ; Schols D; Breslin HJ; Woestenborghs R; Desmyter J; Janssen MA; De Clercq E
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2863-70. PubMed ID: 7535037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virus.
    Debyser Z; De Vreese K; Pauwels R; Yamamoto N; Anné J; De Clercq E; Desmyter J
    J Gen Virol; 1992 Jul; 73 ( Pt 7)():1799-804. PubMed ID: 1378481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
    Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
    Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors.
    Taylor PB; Culp JS; Debouck C; Johnson RK; Patil AD; Woolf DJ; Brooks I; Hertzberg RP
    J Biol Chem; 1994 Mar; 269(9):6325-31. PubMed ID: 7509800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of the acquired immune deficiency syndrome (AIDS): non-nucleoside inhibitors of the human immunodeficiency virus type 1 reverse transcriptase.
    De Clercq E
    Int J Immunopharmacol; 1991; 13 Suppl 1():83-9. PubMed ID: 1726686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a thiobenzimidazolone derivative on DNA strand transfer catalyzed by HIV-1 reverse transcriptase.
    Gopalakrishnan V; Benkovic S
    J Biol Chem; 1994 Feb; 269(6):4110-5. PubMed ID: 7508439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates.
    White EL; Buckheit RW; Ross LJ; Germany JM; Andries K; Pauwels R; Janssen PA; Shannon WM; Chirigos MA
    Antiviral Res; 1991 Oct; 16(3):257-66. PubMed ID: 1725247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.
    Shao X; Rytting AS; Ekstrand DH; Vrang L; Källander CF; Gronowitz JS
    Antivir Chem Chemother; 1998 Mar; 9(2):167-76. PubMed ID: 9875388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
    Buckheit RW; Fliakas-Boltz V; Yeagy-Bargo S; Weislow O; Mayers DL; Boyer PL; Hughes SH; Pan BC; Chu SH; Bader JP
    Virology; 1995 Jun; 210(1):186-93. PubMed ID: 7540784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.
    Baba M; De Clercq E; Tanaka H; Ubasawa M; Takashima H; Sekiya K; Nitta I; Umezu K; Nakashima H; Mori S
    Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2356-60. PubMed ID: 1706522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates.
    Ueno T; Shirasaka T; Mitsuya H
    J Biol Chem; 1995 Oct; 270(40):23605-11. PubMed ID: 7559526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.